How Does 340B Impact the Economics of a Drug?
Perspectives by the Leerink Center for Pharmacoeconomics
Podcast: October 7, 2026
A 304B 101 with Sabrina Aery.
Thought Leadership
Analysis of 340B Modifier Usage in Medicare Part B claims
ADVI Health’s Strategic Analytics, Value and Economics (SAVES) team in collaboration with Aery Policy & Access Partners, LLC
Published: September 2026
Analysis of the incidence of 340B modifiers on Medicare Part B drug claims for the period January 2025 through June 2026.
Analysis of 340B modifier usage in Medicare Part D claims for IPAY 2026 and IPAY 2027 selected drugs
ADVI Health’s Strategic Analytics, Value and Economics (SAVES) Team In collaboration with Aery Policy & Access Partners, LLC
Published: April 2026
Focused analysis of the utilization of a voluntary 340B modifier on Medicare Part D claims for drugs selected for Maximum Fair Prices (MFPs) under the Inflation Reduction Act (IRA) in 2026 and 2027 to inform future policy development.
Issues and Challenges with the Effectuation of Maximum Fair Prices for Medicare Part B Drugs
Association of Value Based Cancer Care, in conjunction with ADVI and Aery Policy & Access Partners, LLC
Published October 2025
Comprehensive examination of the policy context and operational challenges facing patients, physicians, manufacturers, wholesalers, and other stakeholders with the effectuation of MFPs for Part B drugs. This also explores what CMS and policymakers should consider between now and when the policy goes into effect in January 2028.
Previous Speaking Highlights
-
April 27 - 30
Two Panels:
“A Fireside Chat with Rujul Desai, CMS and Marc Samuels, ADVI Health” and “Evolving US Policy and Value Economics Shaping the Future of Specialty Pharmacy”
learn more > -
March 25 - 27, 2026
“Crystal Ball Panel”
learn more > -
February 7, 2026
Guest Lecturer -
February 12, 2026
Moderating
Policy Power Players: How Industry Voices are Shaping Global Access in a Post-US Election Era
learn more > -
March 20, 2026
The IRA's Drug Pricing Provisions from All Sides
learn more > -
Drug Pricing and Market Access: Key Takeaways from 2025 and Outlook for 2026
listen here> -
November 19 - 20, 2025
The 15th Annual Summit assist life sciences companies in delivering more effective forecasts, enhanced visibility, profitability and control through best practices for Gross-to-Net management.
learn more > -
November 13, 2025
The BRG Washington Healthcare Policy Forum offers a dynamic half-day program featuring insights from Washington, DC, health policy leaders on key developments shaping 2026. Topics include the Trump administration's policy and regulatory changes impacting healthcare investors, current priorities and challenges in Medicaid policy, emerging private equity trends, and more.
learn more > -
October 22 - 24, 2025
The Association for Value Based Cancer Care’s 15th Annual Summit brings together stakeholders and leaders for in-depth discussions, educations, and networking.
learn more > -
October 10, 2025
A one-day convening of scholars, policymakers, advocates, and industry stakeholders to examine the early implementation of the Inflation Reduction Act’s drug pricing provisions, and celebrate the anniversary of Medicare Part D.
learn more >